通过适应性放射治疗 (ReSTART) 降低唾液毒性:一项随机对照试验,将常规IMRT与头部和部状细胞癌中的适应性IMRT进行比较
S Ghosh Laskar1, S Sinha1, A Kumar1
1Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
Clinical oncology (Royal College of Radiologists (Great Britain))
|April 4, 2024
概括
该ReSTART试验调查了自适应性放射治疗 (ART) 是否降低了头部和部状细胞癌 (HNSCC) 患者的唾液毒性. 这一III期试验将标准IMRT与ART进行比较,使用scintigraphy来评估异口症.
科学领域:
- 辐射瘤学 辐射瘤学
- 头部和部癌症 治疗 治疗
- 临床试验 临床试验
背景情况:
- 适应性放射疗法 (ART) 在减少头部和部状细胞癌 (HNSCC) 的异位形成方面表现有前途.
- 有限的随机证据证明ART在HNSCC治疗中的有效性.
- 以前的研究表明,ART可以降低腺辐射剂量.
研究的目的:
- 与标准强度调节放射治疗 (IMRT) 相比,评估适应性放射治疗 (ART) 在降低唾液毒性的有效性.
- 为了评估唾液毒性的初级终点,在辐射后12个月使用唾液光学.
- 为了比较二次终点,包括急性和晚期毒性,生存率和生活质量.
主要方法:
- ReSTART试验是针对局部发达HNSCC的第三期随机研究.
- 患者接受标准IMRT (5毫米规划目标体积差) 或ART (3毫米PTV差与自适应规划).
- 主要终点是毒性,通过12个月的剪切图评估;需要130名患者.
主要成果:
- 本节不适用,因为该研究正在进行中,结果尚未提供.
结论:
- ReSTART试验解决了关于HNSCC中ART的关键问题,特别是在资源有限的环境中.
- 独特的方面包括在ART手臂中减少PTV边际,以及基于光束成像的静止体评估.
- 该试验旨在提供强有力的随机证据,证明ART对HNSCC患者的益处.
相关概念视频
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
200
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
200